Androgen deprivation therapy (ADT) has been and continues to be the most common treatment for men with advanced prostate cancer and is now used earlier in the continuum of care for prostate cancer. Unfortunately, the majority of prostate cancer patients on ADT will develop a castration-resistant form of the disease that is responsible for the majority of the morbidity and mortality related to prostate cancer. Given recent advances, there are now therapeutic options available that can reduce the morbidity and improve survival in patients with castrationresistant prostate cancer (CRPC). Research is intensifying in this area and further improvements can be expected in the near future. This review will briefly summarize what is currently available and propose strategies for the management of CRPC.
The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer